NCT01665417 - Icotinib as First-line and Maintenance Treatment in EGFR Mutated Patients With Lung Adenocarcinoma | Biotech Hunter

Enrollment

100

Participants

Timeline

Start Date

August 31, 2012

Primary Completion Date

July 31, 2017

Study Completion Date

December 31, 2017

Conditions

EGFR Positive Non-small Cell Lung CancerAdenocarcinoma

Interventions

DRUG

Experimental

Icotinib: 125mg, oral administration, three times per day.

DRUG

Chemotherapy

Chemotherapy Regimen 1：Pemetrexe 500 mg/m\^2 on Day 1, Cisplatin 75 mg/m\^2 on Day 1, 21 days/1 cycle, 2/4 cycles totally, until progression, withdrawal of consent, or unacceptable toxicity.

DRUG

Chemotherapy

Chemotherapy Regimen 2：Docetaxel 75 mg/m\^2 on Day 1, Cisplatin 75 mg/m\^2 on Day 1, 21 days/1 cycle, 2/4 cycles totally, until progression, withdrawal of consent, or unacceptable toxicity.

Trial Locations (1)

100853

RECRUITING

Chinese People's Liberation Army (PLA) General Hospital, Beijing